NextCure (NXTC) Earnings Date & Reports

Key Takeaways

• NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs, a type of cancer therapy that links a drug to an antibody to target tumor cells), is expected to report fiscal third-quarter 2026 results in early November 2026.
• Wall Street consensus calls for a net loss of about $0.90 per share, with revenue expected near $0, consistent with the company's pre-revenue, clinical-stage status.
• The company has beaten consensus EPS (earnings per share) estimates in four of its last eight quarters, but it missed expectations in its most recent report, posting a loss of $2.80 per share versus a $1.95 loss consensus in Q2 2026.
• Investors are closely watching the company's cash position, given management has previously raised "substantial doubt" about its ability to continue as a going concern.
• Clinical catalysts, including the SIM0505 and LNCB74 programs, remain central to the investment narrative heading into the print.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages available for NextCure.
• You can also explore Trending AI Robots to see how automated trading strategies are positioned across the market.

Earnings Context and Why It Matters

NextCure's upcoming quarterly earnings report carries outsized weight because the company operates at a critical financial and strategic crossroads. As a pre-revenue biotech, its quarterly results are less about sales growth and more about operating discipline, cash burn, and pipeline momentum. In recent quarters, management has flagged substantial doubt about the company's ability to continue as a going concern, making each earnings release a key checkpoint for investors assessing liquidity and funding runway. The company has also undergone a strategic pivot, announcing a transformational merger with Avere Therapeutics alongside workforce reductions, while deprioritizing certain legacy programs. Against that backdrop, this report will help investors gauge whether cost controls are taking hold and whether the repositioned pipeline can support the company's next chapter.

Earnings Expectations

Analysts expect NextCure to report a net loss of approximately $0.90 per share for its fiscal third quarter of 2026, with revenue expected to come in at roughly $0, reflecting the company's clinical-stage status and absence of commercialized products. For context, the company reported a loss of $3.22 per share in the same quarter a year earlier, so consensus implies a meaningfully narrower loss year over year. In its most recent quarter (Q2 2026), NextCure posted a loss of $2.80 per share, missing the consensus estimate of a $1.95 loss by $0.85. That miss was driven in part by a non-cash asset impairment charge. While NextCure has beaten consensus EPS estimates in four of its last eight quarters, the recent miss underscores the volatility of quarterly results at this stage of the company's development. Given the pre-revenue profile, investors will focus less on top-line figures and more on operating expense trends, cash burn, and commentary on the pipeline.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking NextCure and its peers in the biotech space, the AI Screener offers a streamlined way to surface candidates that match specific criteria and monitor evolving market conditions.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around NextCure remains cautious, shaped primarily by liquidity concerns and the company's strategic pivot. The stock has been highly volatile, and its implied post-earnings move has historically been elevated, reflecting the binary nature of clinical-stage biotech updates. Investors will be listening closely for any change in the going-concern language, updates on financing efforts, and clarity on the merger with Avere Therapeutics. Key risk factors include the potential for further dilution if the company raises capital, delays in clinical data readouts, and continued cash burn. Conversely, any signal of an extended runway or positive pipeline progress could be viewed favorably, though expectations appear measured ahead of the print.

Forward Outlook and Key Factors to Monitor

Looking beyond the upcoming report, several factors will shape NextCure's trajectory. First and foremost is liquidity. With management having previously disclosed substantial doubt about its ability to continue as a going concern, investors should monitor the company's cash balance and any commentary on additional financing, partnerships, or cost-reduction measures.

The clinical pipeline remains the other major pillar of the story. The SIM0505 program, which received FDA (U.S. Food and Drug Administration) Fast Track designation for platinum-resistant ovarian cancer in April 2026, is a key area of focus, with dose optimization underway. Meanwhile, LNCB74 continues through Phase 1 testing, with proof-of-concept data expected in the second half of 2026.

The proposed merger with Avere Therapeutics is another important catalyst to watch. How that transaction progresses, and how it reshapes the company's portfolio and capital structure, could have a significant bearing on the outlook. Investors should also keep an eye on operating expense trends and whether the company's restructuring efforts translate into a more sustainable cost base. These dynamics will be central to the company's ability to extend its runway and advance its programs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations